Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: Case report with literature review

Journal of B.U.ON.

Volumn 12, Issue 1, 2007, Pages 129-132

  Grudeva Popova, Janet ^a   Yaneva, M ^a   Zisov, K ^a   Ananoshtev, N ^a  

^a UNIVERSITY HOSPITAL ST GEORGE   (Bulgaria)

Author keywords

Acute promyelocytic leukemia; Radiotherapy; Secondary malignancy; Thyroid cancer

Indexed keywords

IDARUBICIN; IODINE 131; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; ANTINEOPLASTIC AGENT; RADIOACTIVE IODINE;

ADULT; ANAMNESIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; CYTOGENETICS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSERYTHROPOIESIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LABORATORY TEST; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; POOR GENERAL CONDITION; POSTOPERATIVE CARE; PROMYELOCYTIC LEUKEMIA; RADIATION DOSE; SIDE EFFECT; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIATION INJURY; REVIEW; THYROID TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 34249689749     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sherman S. Thyroid carcinoma. Lancet 2003; 361: 501-511.
2. Mazzaferri E, Kloos R. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Endocrinol Metab 2002; 86: 1447-63.
3. Schlumberger M, Berg G, Cohen O et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150: 105-112.
4. Passler C, Scheuba C, Prager G et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocrine Rel Cancer 2004; 11: 131-139.
5. Maurici E, Anselmo A, Osti M et al. Analysis of the risk of solid tumor following Hodgkin's disease. Haematologica 1997; 82: 57-63.
6. Schilling R, Abellan F, Esscribano D et al. Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica 1998; 83: 767-768.
7. Richards EM, Marcus RE. Acute promyelocytic leukemia following radioiodine therapy. Clin Lab Haematol 1993; 15: 55-58.
8. Laurenti L, Salutari P, Sica S et al. Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 1998; 76: 271-272.
9. Sanz M, Guillermo M, Marcos G et al. Risk-adapted treatment of acute promyelocytic leukemia with all-transretinoic acid and anthracycline monochemotherapy: a multicenter study by PETHEMA group. Blood 2004; 103: 1237-1241.
10. Beaumont M, Sanz M, Carli PM etal. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2123-2137.
11. Yin C, Glassman A, Lin P et al. Morphologic, Cytogenetic, and Molecular Abnormalities in Therapy-Related Acute Promyelocytic Leukemia. Am J Clin Path 2005; 124: 840-848.
12. Schoch C, Kern W, Schnittger S et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120-125.
13. Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago Series. Blood 2003; 102: 43-52.
14. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39: 6-11.
15. Swerdlow A, Barber J, Hudson G et al. Risk of Second Malignancy After Hodgkin's Disease in a Collaborative British Cohort: The Relation to Age at Treatment. J Clin Oncology 2000; 18: 498-504.
16. Bhatia S, Robison L, Oberlin O et al. Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease. N Engl J Medicine 1996; 334: 745-751.
17. Schlumberger M, de Vathaire F. 131 iodine: medical use. Carcinogenic and genetic effects. Ann Endocrinol 1996; 57: 166-176.
18. Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol 1992; 168: 337-343.
19. de Vathaire F, Schlumberger M, Delisle MJ et al. Leukemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75: 734-739.